Studies have shown that in NSCLC cell models and animal models, engineered MSC-derived exo-mediated miR-631 delivery could control NSCLC malignant behaviours by regulating the transcription factor 2/phosphatidylinositol 3-kinase/Akt signalling pathway [72]. Here, AKT1 is linked to non-small cell lung carcinoma.